Daihan Pharmaceutical Co.,Ltd. (KOSDAQ:023910)
South Korea flag South Korea · Delayed Price · Currency is KRW
30,000
+150 (0.50%)
At close: Jun 18, 2025, 3:30 PM KST

Daihan Pharmaceutical Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Operating Revenue
205,067204,195195,911184,268171,463166,080
Upgrade
Other Revenue
-0----0-
Upgrade
Revenue
205,067204,195195,911184,268171,463166,080
Upgrade
Revenue Growth (YoY)
3.13%4.23%6.32%7.47%3.24%-1.59%
Upgrade
Cost of Revenue
135,973134,788130,599124,455115,781109,885
Upgrade
Gross Profit
69,09469,40765,31259,81255,68256,195
Upgrade
Selling, General & Admin
28,68628,42826,94525,44524,92324,892
Upgrade
Research & Development
2,1451,8021,641567.87790.59689.17
Upgrade
Other Operating Expenses
464.97479.63411.75387.26334.4303.68
Upgrade
Operating Expenses
31,89031,32729,51726,84426,61426,232
Upgrade
Operating Income
37,20438,08135,79532,96829,06829,963
Upgrade
Interest Expense
-2.33-1.81-52.47-593.43-469.27-617.06
Upgrade
Interest & Investment Income
1,6621,47587.18486.66506.7421.05
Upgrade
Currency Exchange Gain (Loss)
1,0031,229504.71525.35687.03-426.96
Upgrade
Other Non Operating Income (Expenses)
1,1731,18487.5773.92599.56822.93
Upgrade
EBT Excluding Unusual Items
41,04041,96736,42233,46130,39230,163
Upgrade
Gain (Loss) on Sale of Investments
393.36303.6288.69---
Upgrade
Gain (Loss) on Sale of Assets
59.458.0322.53-9.441.2819.72
Upgrade
Asset Writedown
------7,650
Upgrade
Pretax Income
41,49242,32936,73433,45130,43322,532
Upgrade
Income Tax Expense
8,3538,5698,3078,4917,7635,151
Upgrade
Net Income
33,13933,75928,42624,96122,67017,381
Upgrade
Net Income to Common
33,13933,75928,42624,96122,67017,381
Upgrade
Net Income Growth
12.78%18.76%13.88%10.10%30.43%-38.29%
Upgrade
Shares Outstanding (Basic)
666666
Upgrade
Shares Outstanding (Diluted)
666666
Upgrade
Shares Change (YoY)
---1.75%-0.25%--
Upgrade
EPS (Basic)
5635.885741.344834.414170.673778.402896.80
Upgrade
EPS (Diluted)
5635.885741.344834.414170.673778.402896.80
Upgrade
EPS Growth
12.78%18.76%15.92%10.38%30.43%-38.29%
Upgrade
Free Cash Flow
20,08219,84117,58020,37828,76728,267
Upgrade
Free Cash Flow Per Share
3415.293374.382989.793405.014794.574711.20
Upgrade
Gross Margin
33.69%33.99%33.34%32.46%32.48%33.84%
Upgrade
Operating Margin
18.14%18.65%18.27%17.89%16.95%18.04%
Upgrade
Profit Margin
16.16%16.53%14.51%13.55%13.22%10.46%
Upgrade
Free Cash Flow Margin
9.79%9.72%8.97%11.06%16.78%17.02%
Upgrade
EBITDA
44,50145,36244,45942,17640,47941,263
Upgrade
EBITDA Margin
21.70%22.21%22.69%22.89%23.61%24.85%
Upgrade
D&A For EBITDA
7,2977,2828,6639,20811,41111,300
Upgrade
EBIT
37,20438,08135,79532,96829,06829,963
Upgrade
EBIT Margin
18.14%18.65%18.27%17.89%16.95%18.04%
Upgrade
Effective Tax Rate
20.13%20.24%22.61%25.38%25.51%22.86%
Upgrade
Advertising Expenses
-99.7678.6993.6763.1848.89
Upgrade
Updated Mar 1, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.